Valerio Therapeutics S.A.
PAR: ALVIO.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Julien Miara
- Employees
- 38
- Headquarters
- Paris, France
- IPO year
- 2023
- Market cap
- €59.4M
- Website
- https://valeriotx.com
Loading ALVIO…
Loading profile data…Frequently asked questions about ALVIO
What does Valerio Therapeutics S.A. (ALVIO.PA) do?
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which...
Where does ALVIO.PA trade?
Valerio Therapeutics S.A. (ALVIO.PA) trades on the Euronext Paris.
What sector is ALVIO.PA in?
Valerio Therapeutics S.A. (ALVIO.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Valerio Therapeutics S.A.?
Julien Miara is the chief executive officer of Valerio Therapeutics S.A. (ALVIO.PA).
Where is Valerio Therapeutics S.A. headquartered?
Valerio Therapeutics S.A. is headquartered in France.
Does ALVIO.PA pay a dividend?
Valerio Therapeutics S.A. (ALVIO.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALVIO.PA go public?
Valerio Therapeutics S.A. (ALVIO.PA) completed its initial public offering in 2023.